"Prevention might be better than treatment in cancer treatment" is brief conclusion drawn from war on cancer through National Cancer Act of 1971 by U.S. President Richard Nixon. However, the clinical practice of chemoprevention is still in its infancy in spite of a wealth of data showing its effectiveness in experimental animals as well as in vitro mechanism research. Recent advances in either high throughput analysis including cancer genomes and tailored medicine or molecular targeted therapeutics, preventive strategies also should be changes as previous preventive strategies including phytoceuticals, life-style modification, and some empirical agents. Furthermore, molecular targeted therapeutics achieved high goal of effectiveness under the concept of therapeutic or preventive "synthetic lethality", of which extended application can be included within the scope of chemoprevention. Here, we will summarize several recent advances in chemopreventive strategy objected to justify optimism that chemoprevention will be an effective approach for the control of human cancer. siTRP (short-term intervention to revert premalignancy) strategy will be introduced for cancers in gastroenterology. (J Cancer Prev 2013;18:289-297) 
INTRODUCTION
Prof. Hong WK and Prof. Sporn MB, for the first time, defined chemoprevention as follows; chemoprevention is the use of pharmacologic or natural agents to inhibit the development of invasive cancer, for which either blocking the DNA damage that initiates carcinogenesis or arresting/ reversing the progression of premalignant cells in 1997 ( Fig. 1) . 1 Since carcinogenesis is a process consisting of initiation, promotion and progression phases, this multistage sequence of carcinogenesis events has provided the opportunity for intervention to inhibit, revert or delay each process of carcinogenic stage before the development of invasive malignancy. Therefore, agents that can repress, detour, tackle, or revert this unpleasant journey to cancer have great potential for chemoprevention. An ideal chemopreventive agent should have little or no toxicity, high efficacy in multiple sites, capability of oral consumption, known mechanisms of action, and low cost and feasibility of long-term administration, by which mostly natural products or phytoceuticals had been identified.
Until now, a variety of grains, cereals, nuts, soy products, olives, beverages such as chocolate, tea, and coffee, spices such as turmeric, garlic, ginger, black pepper, curcumin, and vegetables including cabbage, garlic, cauliflower, broccoli, tomatoes, and fruits such as, apples, grapes, and berries, and famous Korean red ginseng confer a protective effect against cancer, in which natural products contain a wide variety of biologically active phytochemicals including phenolics, flavonoids, carotenoids, alkaloids, gin- The evidence that mutation in tumor suppressors such as BRCA1/2 makes cancer cells highly susceptible to inhibitors of a compensatory DNA repair pathway has broadened the range of possible therapeutic targets by extending it to gene products that are in a "synthetic lethality" relationship with oncogenes and tumor suppressors. 4 Inhibition of such targets blocks specific buf- we are and what we want to achieve as cancer prevention researchers and practitioners and the novel strategy will be introduced in later part of review article.
SYNTHETIC LETHALITY FOR THERAPEUTIC OR PREVENTIVE EFFICACY OF CANCER
Curing advanced cancer requires the simultaneous use of 2 or more drugs. 8 Successful uses of combination chemotherapeutics and subsequent advances in cancer biology led to the recognition that frequent relapses after response to cancer therapy are because of multiple pathways that can enable resistant cancer cell populations to survive.
With the increased understanding of the genetic origin of cancer and the recognition that the major phases of cancer development, a critical milestone for understanding carcinogenesis at a molecular level, the development of specific molecularly targeted therapies became possible.
As representational example, the initial documented suc- Though reflux disease is a key factor for development of Barrett's esophagus, other factors must underlie its development since it occurs in only a minority of reflux disease patients. 20 However, dominant pathogenic mechanism is that gastroduodenal content reflux from gastroesophageal reflux disease induces the inflammation-mediated progression from hyperplasia to metaplasia, and to adenocarcinoma, 21 by which several pharmacological interventions are anticipated as cancer preventive way, including proton pump inhibitor (PPI including esomeprazole, rabeprazole, and pantoprazole), aspirin, NSAIDs, and some more anti-inflammatory agents. Fig. 3A ) to rejuvenate atrophic gastritis into non atrophic change targeted to tackle the progression to H. pylori gastritis in high risk patients (Fig.   3B ).
Colitis-associated cancer and colon adenoma
The risk of developing colorectal cancer is increased in we have published data regarding chemoprevention of colitic cancer using infliximab 31 and 8-OHdG. 32 Apart from colitic cancer, colorectal carcinogenesis is also based on a multi-step process characterized by molecular and cellular alterations that result in an identifiable precursor lesion, ie, the adenomatous polyp. 33 The transition from normal mucosa to adenoma and its subsequent progression to carcinoma are protracted events that offer opportunities for preventive interventions. In detail, regular and continued use of non-steroidal anti-inflammatory drugs (NSAIDs) and predominantly aspirin is associated with significant reductions in both colorectal adenoma and carcinoma incidence. 34 However, since long-term use of NSAIDs is associated with substantial GI toxicity and may cause an exacerbation in IBD patients, selective COX-2 inhibitors, with a better toxicity profile and no flare-up in IBD disease activity, are therefore attractive candidates for prevention. 35 Apart from aspirin and NSAIDs, calcium carbonate is the only other agent that has been shown to modestly reduce sporadic adenoma recurrence rates in a randomized trial.
Folate and selenium are being actively studied based on provocative preclinical data. 36 Effective anti-inflammatory agents as well as biologics under colonoscopic surveillance can be included as siTRP strategy for colitic cancer and safe warrant novel NSAIDs as siTRP strategy for colon adenoma (Fig. 3C ).
Chronic fibrosing pancreatitis and pancreatic cancer
Chronic pancreatitis is characterized by progressive fibrosis, pain and loss of exocrine and endocrine functions and the long-standing chronic pancreatitis and its associated pancreatic fibrosis are the most common pathogenic events involved in human pancreatic carcinogenesis. 37 Since pancreatic cancer has an extremely poor prognosis and the cellular mechanisms contributing to pancreatic cancer are relatively unknown, prevention of pancreatic cancer might be the better way to save patient life much more than the development of chemotherapeutics. cancer. 38 Our group also added more evidence that antioxidant can tackle to way from chronic pancreatitis to pancreatic cancer. 42 Potent antioxidant or anti-protease agents can be included as siTRP agent for amelioration of chronic fibrosing pancreatitis.
PERSPECTIVE OF CANCER PREVENTION ADOPTING siTRP STRATEGY IN CLINIC
The continuing magnitude and burdening of the cancer problem make it imperative to develop an innovative preventive approach to this disease. As advances in the molecular and cellular biology of carcinogenesis continue, specific targets for preventive intervention are being profusely identified, and effective new chemopreventive
agents are being synthesized and tested. As much as current molecular therapeutics and application of synthetic lethality, in the near future, molecular targeted chemoprevention will shed the new hope for cancer conquest based on a mechanistic understanding of carcinogenesis and tailored chemoprevention. Especially further understanding of inflammatory mediators and stem cell biology, rejuvenation of chronic degenerative diseases as well as chemoprevention will be tried before irreversible change of carcinogenesis, so called, siTRP will be come true. 43 Results from our laboratory strongly suggested the high possibility of reverting into non-tumorous condition through short-term intervention. Among target for future chemoprevention, Kim et al. 44 provided an overview of the role of oxidative stress in inflammation-based GI tract diseases, including reflux esophagitis, H. pylori-associated gastritis, non-steroidal anti-inflammatory drug-induced enteritis, ulcerative colitis, and associated colorectal cancer. The challenging issue that ROS can contribute to diverse gastrointestinal dysfunction, or manifest dual roles in cancer promotion or cancer suppression will be the opportunity to enhance prevention of inflammation-based GI carcinogenesis.
